Pesquisar
Radiopharm Theranostics Ltd
RADXAdicionar à lista de desejos
4.370USD
+0.100+2.34%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
0.00Valor de mercado
--P/L TTM
Mais detalhes de Radiopharm Theranostics Ltd Empresa
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Informações de Radiopharm Theranostics Ltd
Código da empresaRADX
Nome da EmpresaRadiopharm Theranostics Ltd
Data de listagemNov 25, 2021
CEOCanevari (Riccardo)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscal- -
EndereçoLevel 3, 62 Lygon Street
CidadeMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3053
Telefone61398245254
Sitehttps://radiopharmtheranostics.com/
Código da empresaRADX
Data de listagemNov 25, 2021
CEOCanevari (Riccardo)
Executivos da empresa Radiopharm Theranostics Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Phillip Hains
Mr. Phillip Hains
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Bruce Goodwin
Mr. Bruce Goodwin
Non-Executive Director
Non-Executive Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Riccardo Canevari
Mr. Riccardo Canevari
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Mr. Paul Hopper
Mr. Paul Hopper
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Thomas H. (Thom) Tulip, Ph.D.
Dr. Thomas H. (Thom) Tulip, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Dimitris Voliotis, M.D.
Dr. Dimitris Voliotis, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Hester Larkin
Ms. Hester Larkin
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ian Turner
Mr. Ian Turner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Radiopharm Theranostics Ltd?
Os cinco principais acionistas de Radiopharm Theranostics Ltd são: Mr. Riccardo Canevari
Quantas instituições possuem ações da Radiopharm Theranostics Ltd (RADX)?
Em 2026Q1, 11 instituições possuíam ações da Radiopharm Theranostics Ltd, com valor de mercado aproximado de 51.39M, representando 3.30% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 50862187.00.